anti-Influenza A, Puerto Rico 8/34 antibody product blog
Tags: Antibody; Monoclonal Antibody; Influenza A, Puerto Rico 8/34; anti-Influenza A, Puerto Rico 8/34 antibody;
The Influenza A, Puerto Rico 8/34 n/a (Catalog #MBS632771) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. MyBioSource\'s Influenza A, Puerto Rico 8/34 can be used in a range of immunoassay formats including, but not limited to, Immunofluorescence (IF).Suitable for use in Immunofluorescence. Researchers should empirically determine the suitability of the Influenza A, Puerto Rico 8/34 n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Influenza virus is a single-stranded RNA virus, segmented, 70nm diameter and enveloped. Strains are described by geographic origin, strain number, year of isolation, hemagglutination (H) and neuraminidase (N) antigens. It is an acute viral disease of the uper respiratory tract characterized by fever, headache, chills, myalgia, weakness, runny nose and sore throat. Cough can be severe. Nausea and vomiting are uncommon. Fatality is generally low, except for those with chronic lung or heart conditions.
Immunogen: Influenza A/Puerto Rico/8/34 (H1N1) and A/Bangkok/ 1/ 79 (H3N2) viruses. Hybridoma: Spleen cells from BALB/c mice were fused with cells of the P3 Ag8.653 mouse myeloma cell line. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing Influenza A, Puerto Rico 8/34 are readily searchable from our website. Different antibodies against the same target such as Influenza A, Puerto Rico 8/34 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.